Trials / Completed
CompletedNCT02960438
A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate
A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 273 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study in rheumatoid arthritis participants inadequately responding to methotrexate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E6011 | subcutaneous administration |
| DRUG | Placebo | subcutaneous administration |
Timeline
- Start date
- 2016-10-20
- Primary completion
- 2018-02-28
- Completion
- 2019-09-17
- First posted
- 2016-11-09
- Last updated
- 2021-06-21
- Results posted
- 2021-06-21
Locations
90 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02960438. Inclusion in this directory is not an endorsement.